🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket

Published 28/02/2023, 12:57
© Reuters.  Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket
IXIC
-
GYRE
-

Benzinga - Gainers

  • Catalyst Biosciences Inc (NASDAQ: CBIO) rose 105% to $0.49 in pre-market trading. South Korea's GC Biopharma said it has signed an asset purchase agreement with Catalyst Biosciences to acquire 3 programs related to the orphan hematology disorders.
  • Intelligent Living Application Group Inc. (NASDAQ: ILAG) rose 40.3% to $1.74 in pre-market trading after the company announced plans to develop advanced smart home security devices.
  • Obseva SA (NASDAQ: OBSV) shares rose 24.4% to $0.12 in pre-market trading after gaining over 16% on Monday. ObsEva announced strategic reorganization to consolidate operations in Switzerland.
  • Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) rose 23.1% to $0.3244 in pre-market trading. Adamis Pharmaceuticals and DMK Pharmaceuticals announced agreement and plan of merger.
  • Mount Rainier Acquisition Corp (NASDAQ: RNER) rose 19.8% to $6.05 in pre-market trading. Mount Rainier Acquisition shares dropped 46% on Monday possibly after the company's general meeting was cancelled on Sunday.
  • Lion Group Holding Ltd. (NASDAQ: LGHL) rose 15.9% to $0.40 in pre-market trading after dropping 10% on Monday.
  • Progyny Inc (NASDAQ: PGNY) shares rose 14.6% to $35.62 in pre-market trading after the company reported better-than-expected Q4 results.
  • AIM ImmunoTech Inc (NYSE: AIM) rose 14.6% to $0.55 in pre-market trading after dropping over 7% on Monday. AIM ImmunoTech, last month, entered into a sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca.
  • Ocugen Inc (NASDAQ: OCGN) rose 11.7% to $1.09 in pre-market trading. Ocugen announced submission of investigational new drug application with the FDA to initiate Phase 1 clinical trial evaluating OCU200 for the treatment of diabetic macular edema.
  • Smart for Life Inc (NASDAQ: SMFL) shares rose 10.5% to $0.21 in pre-market trading after gaining over 7% on Monday.
Losers
  • Aptinyx Inc (NASDAQ: APTX) shares fell 63.6% to $0.22 in pre-market trading after the company reported results from Phase 2 study of NYX-458 in cognitive impairment associated with Parkinson's disease and dementia with lewy bodies and issued pipeline and corporate update.
  • Verde Clean Fuels Inc (NASDAQ: VGAS) fell 18.8% to $10.00 in pre-market after dropping around 17% on Monday.
  • Adapthealth Corp (NASDAQ: AHCO) fell 18.3% to $17.95 in pre-market trading after the company posted a loss for the fourth quarter.
  • Lucira Health Inc (NASDAQ: LHDX) fell 14.7% to $0.43 in pre-market trading. Lucira Health shares jumped 264% on Monday after the company announced FDA authorization for its at-home combination COVID-19 & flu test.
  • Sera Prognostics Inc (NASDAQ: SERA) shares dropped 13.9% to $3.40 in pre-market trading after jumping 18% on Monday. The company recently announced top-line data from the AVERT PRETERM TRIAL.
  • NewtekOne Inc (NASDAQ: NEWT) fell 12.8% to $16.80 in pre-market trading following weaker-than-expected Q4 results.
  • COMSovereign Holding Corp (NASDAQ: COMS) fell 7.6% to $3.39 in pre-market trading after gaining around 10% on Monday. COMSovereign recently announced an 80% year-over-year reduction of outstanding secured debt.
  • Performance Shipping Inc (NASDAQ: PSHG) fell 7.4% to $2.50 in pre-market trading. Performance Shipping announced termination of at-the-market offering.
  • Smith Micro Software, Inc. (NASDAQ: SMSI) shares fell 6.9% to $1.48 in pre-market trading. Smith Micro Software shares dropped 36% on Monday after the company announced it received written notice of contract termination from a U.S.-based Tier 1 carrier customer for the company's family safety solution.
  • Milestone Scientific Inc (NYSE: MLSS) fell 6.4% to $0.71 in pre-market trading after surging 18% on Monday. Milestone Scientific announced 510(k) FDA clearance for the use of CompuFlo® Epidural System in thoracic indications.
Now Read This: Wall Street's Most Accurate Analysts Say Hold These 3 Tech Stocks Delivering High-Dividend Yields

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.